Finding a few foes among billions of cellular friends

February 26, 2014
Finding a few foes among billions of cellular friends
An enzyme-free detection system was used to quantify just a handful of circulating tumor cells. Comprising Fe3O4 beads decorated with bimetallic nanocages, the hybrid electrocatalyst is a hardy alternative to the natural enzyme horseradish peroxidase for cytosensing. Credit: American Chemical Society

Beating cancer is all about early detection, and new research from the University of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a handful of lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells.

The researchers have constructed an ultrasensitive nanoprobe that can electrochemically sense as few as four circulating , and it doesn't require any enzymes to produce a detectable signal.

"That makes it a very robust system," says Hui Wang, a chemist in the university's College of Arts and Sciences who led the research team with South Carolina colleague Qian Wang and Jun-Jie Zhu of Nanjing University. "We show that it's much less sensitive to pH and temperature than the natural enzyme horseradish peroxidase, a traditional means of enhancing sensitivity."

Cancer can metastasize by releasing tumor cells that are capable of spreading the disease to new parts of the body. But the circulating cells also represent a golden opportunity for modern medicine: detecting them in a patient is a telltale sign of a tumor.

They're tough to find, though. In a billion , there might be just one circulating tumor cell that could trip an alarm.

The enzyme-free detection system is based on the electrochemical properties of Fe3O4 nanoparticles, which since 2007 have been known to mimic the peroxide-reducing capacity of horseradish peroxidase. Wang's team was surprised to find that the nanoparticles could also catalyze the electrochemical reduction of small dye molecules, such as thionine, even in the absence of peroxide.

Wang and his team recently reported in the Journal of the American Chemical Society how they decorated Fe3O4 beads with bimetallic nanocages to create a hybrid electrocatalyst. Circulating tumor cells that were trapped onto an electrode surface with cell-targeting aptamers were detected by cyclic voltammetry of thionine. The system had a wide linear response range and a detection limit down to just a few cells.

There's still a long way to go to get a device into the clinic, but Wang can see the potential of the sturdy inorganic nanoprobes.

"We can actually quantify the biomarkers expressed on cancer cells, and because the expression levels on the cancer cells are quite different from the , we can actually identify the cancer cells," he says. "Since the sensitivity is really high, if you have low-abundance in the body, we should be able to detect them."

Explore further: Macrophages target tumor cells following monoclonal antibody therapy

More information: J. Am. Chem. Soc., 2014, 136 (6), pp 2288–2291 DOI: 10.1021/ja500169y

Related Stories

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

New study shows promise for preventing therapy resistance in tumor cells

January 9, 2014
A new study led by University of Kentucky researchers suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer ...

New breast cancer stem cell findings explain how cancer spreads

January 14, 2014
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes ...

Signature of circulating breast tumor cells that spread to the brain found

April 10, 2013
Some breast tumor circulating cells in the bloodstream are marked by a constellation of biomarkers that identify them as those destined to seed the brain with a deadly spread of cancer, said researchers led by those at Baylor ...

Mdm2 suppresses tumors by pulling the plug on glycolysis

February 24, 2014
Cancer cells have long been known to have higher rates of the energy-generating metabolic pathway known as glycolysis. This enhanced glycolysis, a phenomenon known as the Warburg effect, is thought to allow cancer cells to ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.